{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/nausea-vomiting-in-pregnancy/prescribing-information/cyclizine/","result":{"pageContext":{"chapter":{"id":"f416e06b-d171-5ff0-8c08-5bc1edd42843","slug":"cyclizine","fullItemName":"Cyclizine","depth":2,"htmlHeader":"<!-- begin field b30679c6-cd5b-4169-b045-a77400a652ba --><h2>Cyclizine</h2><!-- end field b30679c6-cd5b-4169-b045-a77400a652ba -->","summary":"","htmlStringContent":"<!-- begin item 72d9d823-6a88-46c1-b028-a77400a64fc1 --><!-- end item 72d9d823-6a88-46c1-b028-a77400a64fc1 -->","topic":{"id":"5d1ac05e-2e14-5b50-9a55-84ebd62fb88a","topicId":"866e168a-d1cc-4f14-ae38-2264dad4909d","topicName":"Nausea/vomiting in pregnancy","slug":"nausea-vomiting-in-pregnancy","lastRevised":"Last revised in November 2020","chapters":[{"id":"2ed30ea1-6303-508e-bc93-066f8ffbbba6","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"81163ec6-a53e-53b1-9990-910cceb0be62","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"9f99e883-ffa1-5d97-b703-d5bfbd68f8d5","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"81c02d2d-db72-591c-9cac-e581388698c4","slug":"changes","fullItemName":"Changes"},{"id":"845aae6a-8e35-57f1-b583-4763434044df","slug":"update","fullItemName":"Update"}]},{"id":"21afb631-a6c0-5829-b00a-3b33bef92b50","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"61081bb4-4afa-59ad-8401-21a133c7ac1e","slug":"goals","fullItemName":"Goals"},{"id":"5e20514d-0378-56ab-a9c4-6adb3b054200","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"5af11c90-393d-59dd-9a48-c750bc1a8a14","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"51bcef1b-8089-52c9-92cc-1fa55932d88b","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"ef8fc985-dc5b-58a5-a2ff-ca6e9d55cfb8","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"f559ccd0-5b31-5044-9e75-d75ab6224e12","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"2664bbce-4231-58ba-94b3-9154bbe463ce","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"474f1c82-889d-5487-9620-c2c4c6869f1b","slug":"definition","fullItemName":"Definition"},{"id":"8eb8a14e-f0bc-5bde-941f-077c2ebf80e8","slug":"causes","fullItemName":"Causes"},{"id":"6086e58d-ce8f-56ba-8bc9-6769de656e20","slug":"associated-factors","fullItemName":"Associated factors"},{"id":"843ada21-2019-53fe-96b9-02ac02e7d0f2","slug":"prevalence","fullItemName":"Prevalence"},{"id":"87b6f2c0-0cd6-59f3-9359-e145dc966385","slug":"complications","fullItemName":"Complications"}]},{"id":"d56e419a-1cce-586b-b99b-a5b8a8990006","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"1f17249a-f4a8-55a7-aac0-221f3958f18f","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"b917da16-f352-5806-8109-438dbc9bbf0b","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"92cdc482-cd10-5234-96f9-a47cf0d7a2d1","fullItemName":"Management","slug":"management","subChapters":[{"id":"110c4bdc-fe27-5536-9a99-bfbcf04edc46","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"93dd4a9b-e268-51a6-ad4d-89d5e9f8a3ab","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"f416e06b-d171-5ff0-8c08-5bc1edd42843","slug":"cyclizine","fullItemName":"Cyclizine"},{"id":"130049ea-689b-545a-a2c3-05f0dd6e75a9","slug":"metoclopramide","fullItemName":"Metoclopramide"},{"id":"b1e3f566-e2f8-55a2-989a-e0a05d5ec1e2","slug":"ondansetron","fullItemName":"Ondansetron"},{"id":"5ab79693-69e2-58b9-b27b-5ccf74d1a7b5","slug":"prochlorperazine","fullItemName":"Prochlorperazine"},{"id":"715f035d-267f-5933-b2b0-7d3ee3bd6430","slug":"promethazine","fullItemName":"Promethazine"}]},{"id":"85b35812-d5b1-58c1-83b2-54c180386588","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"1a1884de-e81c-54af-b11f-6b0868c50cc8","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"8a6cb0f6-92e2-57f4-9a1e-bf9e54371e08","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"4dc13c44-10ce-581a-a0a4-039b81c0c21e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"cb1eb43f-2d9f-59be-8318-3bd84b8d0c3f","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"4b024ff4-e12a-55bd-ae23-668d6ca9e645","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"e5cef950-067b-517f-9adb-2be42bf3be6f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"dbe95893-89e8-5737-9b03-95b5280f9823","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"93dd4a9b-e268-51a6-ad4d-89d5e9f8a3ab","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"ea971b82-b162-5c90-8124-d44efc41a369","slug":"dose","fullItemName":"Dose","depth":3,"htmlHeader":"<!-- begin field e23d9cb9-721a-492d-86b8-a77400a7e37a --><h3>What dosage of cyclizine should I prescribe?</h3><!-- end field e23d9cb9-721a-492d-86b8-a77400a7e37a -->","summary":"","htmlStringContent":"<!-- begin item f6c264a1-6e41-4599-affc-a77400a7e0ed --><!-- begin field 6dbec295-b707-4618-a7fe-a77400a7e37a --><ul><li>Prescribe cyclizine 50 mg orally up to three times a day.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/nausea-vomiting-in-pregnancy/references/\">UKMi, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/nausea-vomiting-in-pregnancy/references/\">ABPI Medicines Compendium, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/nausea-vomiting-in-pregnancy/references/\">RCOG, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/nausea-vomiting-in-pregnancy/references/\">BNF 73, 2017</a>] </p><!-- end field 6dbec295-b707-4618-a7fe-a77400a7e37a --><!-- end item f6c264a1-6e41-4599-affc-a77400a7e0ed -->","subChapters":[]},{"id":"5911d5f8-96f0-5717-b22a-5475687dc8d6","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field ce24ade8-2b50-40f3-8276-a77400a815b3 --><h3>What are the adverse effects of cyclizine?</h3><!-- end field ce24ade8-2b50-40f3-8276-a77400a815b3 -->","summary":"","htmlStringContent":"<!-- begin item e1c01705-dadf-4e0d-ab96-a77400a813a2 --><!-- begin field 3607bb7d-26bc-40c2-8998-a77400a815b3 --><ul><li><strong>Drowsiness</strong> is a significant adverse effect with most of the older antihistamines (such as cyclizine), especially with high doses or in the elderly.</li><li><strong>Other adverse effects include:</strong><ul><li>Blood and lymphatic system disorders — agranulocytosis, leucopenia, haemolytic anaemia, and thrombocytopenia.</li><li>Immune system disorders — hypersensitivity reactions, including anaphylaxis.</li><li>Psychiatric disorders — disorientation, restlessness, nervousness, euphoria, insomnia, and auditory and visual hallucinations.</li><li>Nervous system disorders — somnolence, headache, dystonia, dyskinesia, extrapyramidal motor disturbances, tremor, convulsions, dizziness, decreased consciousness, transient speech disorders, paraesthesia, and generalized chorea.</li><li>Cardiac disorders — tachycardia, palpitations, and arrhythmias.</li><li>Vascular disorders — hypertension and hypotension.</li><li>Respiratory disorders — bronchospasm and apnoea.</li><li>Gastrointestinal disorders — dry mouth, nose and throat; constipation; increased gastric reflux; nausea, vomiting, and diarrhoea; stomach pain; and loss of appetite.</li><li>Hepatobiliary disorders — hepatic dysfunction, hypersensitivity hepatitis, cholestatic jaundice, and cholestatic hepatitis.</li><li>Skin and tissue disorders — urticaria, rash, angio-oedema, allergic skin reactions, and fixed drug eruption photosensitivity.</li><li>Musculoskeletal and connective tissue disorders — twitching and muscle spasms.</li><li>Others — tinnitus, blurred vision and oculogyric crisis, and urinary retention.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/nausea-vomiting-in-pregnancy/references/\">ABPI Medicines Compendium, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/nausea-vomiting-in-pregnancy/references/\">BNF 73, 2017</a>]</p><p> </p><!-- end field 3607bb7d-26bc-40c2-8998-a77400a815b3 --><!-- end item e1c01705-dadf-4e0d-ab96-a77400a813a2 -->","subChapters":[]},{"id":"49e2a1f2-321d-53ab-ac61-b1e8d6f89856","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field e9bc51a3-0dd6-4b45-942f-a77400a7fc7e --><h3>What are the contraindications and cautions when prescribing cyclizine?</h3><!-- end field e9bc51a3-0dd6-4b45-942f-a77400a7fc7e -->","summary":"","htmlStringContent":"<!-- begin item 405867c1-c821-4741-b54c-a77400a7fa03 --><!-- begin field 5aaf5a12-1b3a-4f6d-8ac4-a77400a7fc7e --><ul><li><strong>Do not prescribe cyclizine to:</strong><ul><li>People with severe liver disease — increased risk of coma.</li></ul></li><li><strong>Prescribe cyclizine with caution to people with:</strong><ul><li>Prostatic hypertrophy, urinary retention, susceptibility to angle-closure glaucoma, and pyloroduodenal obstruction.</li><li>Hepatic disease.</li><li>Epilepsy.</li><li>Severe heart failure or acute myocardial infarction — cyclizine may cause a fall in cardiac output associated with increases in heart rate, mean arterial pressure, and pulmonary wedge pressure.</li><li>Porphyria.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/nausea-vomiting-in-pregnancy/references/\">ABPI Medicines Compendium, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/nausea-vomiting-in-pregnancy/references/\">BNF 73, 2017</a>]</p><!-- end field 5aaf5a12-1b3a-4f6d-8ac4-a77400a7fc7e --><!-- end item 405867c1-c821-4741-b54c-a77400a7fa03 -->","subChapters":[]},{"id":"b94230aa-fb4e-55a7-bb1d-902b331e1553","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 1de4b91d-744c-4d1f-bd5a-a77400a82c13 --><h3>What drug interactions occur with cyclizine?</h3><!-- end field 1de4b91d-744c-4d1f-bd5a-a77400a82c13 -->","summary":"","htmlStringContent":"<!-- begin item 8b9f12e4-2adb-4dca-ae27-a77400a82997 --><!-- begin field f94e4acd-5cb3-4b79-822c-a77400a82c13 --><ul><li><strong>Alcohol </strong>— the anti-emetic effect of cyclizine may increase the toxicity of alcohol.</li><li><strong>Antimuscarinic drugs </strong>— there is a risk of increased antimuscarinic adverse effects when cyclizine is given with other antimuscarinic drugs. Concurrent use can also lead to confusion in the elderly.</li><li><strong>Antidepressants </strong>— there is a risk of increased antimuscarinic and sedative effects when cyclizine is given with tricyclic antidepressants and monoamine oxidase inhibitors.</li><li><strong>Central nervous system (CNS) depressant drugs </strong>— cyclizine may have additive effects with other CNS depressants, such as opioid analgesics.</li><li><strong>Ototoxic drugs </strong>— cyclizine may disguise signs indicating the onset of damage caused by ototoxic drugs (such as aminoglycoside antibiotics).</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/nausea-vomiting-in-pregnancy/references/\">ABPI Medicines Compendium, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/nausea-vomiting-in-pregnancy/references/\">BNF 73, 2017</a>]</p><!-- end field f94e4acd-5cb3-4b79-822c-a77400a82c13 --><!-- end item 8b9f12e4-2adb-4dca-ae27-a77400a82997 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}